Are PE Firms Still Buying Med Spa Businesses in 2026?

Yes — PE-backed platforms remain among the most active acquirers in the aesthetics space, even though the white-hot 2021-2022 frenzy has moderated. The institutional money is still being deployed, the consolidation thesis still works at current multiples, and the dermatology-led platforms continue to view med spa acquisitions as the highest-margin extension of their core dermatology practice base.

Med Spa PE Acquisition Snapshot, 2026

  • Typical multiple range: 4.0x-9.0x EBITDA
  • Platform threshold: $1M+ EBITDA for serious PE interest
  • Small single-location (under $500K EBITDA): 3.0x-5.0x SDE
  • Multi-location $2M+ EBITDA platforms: 7.0x-9.0x EBITDA
  • Typical close timeline: 6-10 months engagement to wire

Who's buying med spas in 2026?

The most active strategic and PE-backed buyers fall into three groups. The first is dedicated aesthetics platforms — LaserAway, Ideal Image, Skin Laundry — that build pure-play med spa chains. The second is dermatology-led aesthetics platforms — Advanced Dermatology & Cosmetic Surgery, Dermatology Associates (Quad-C), U.S. Dermatology Partners, Forefront Dermatology, Pinnacle Dermatology, Skin Spectrum — that bolt med spas onto an existing dermatology base. The third is independent regional PE-backed roll-ups buying 3-10 location clusters in specific metros.

Across all three groups, the underwriting threshold for serious PE interest is roughly $1M of adjusted EBITDA. Below that, you are mostly competing for individual and small-platform attention at 3x-5x SDE multiples. Above $1M EBITDA with multi-location footprint, the PE platforms engage seriously and multiples can clear 7x-9x. For a deeper look at how dermatology-led platforms are pricing aesthetics add-ons specifically, see our 2026 dermatology practice valuation analysis.

What PE buyers are scrutinizing harder in 2026

Three things matter more in 2026 than they did three years ago. First, practitioner retention — single-injector concentration above 30% of bookings is a red flag for PE underwriting, and buyers will discount the multiple or require retention escrows. Second, regulatory compliance — state-by-state physician supervision rules vary widely, and PE buyers want documented, defensible medical-director relationships and protocols. Third, revenue diversification — med spas relying on 60%+ of revenue from Botox alone face price compression risk as new neuromodulators continue to enter the market; PE buyers are paying premium multiples for med spas with strong recurring membership programs, body-contouring revenue, skin treatments, and other longer-cycle services.

"I closed a three-location Southeast med spa last winter — $4.8M revenue, $1.2M EBITDA, four injectors with no single one above 28% of bookings, strong membership program at 35% of revenue. The seller had been quoted 5x by a regional competitor 18 months earlier. We ran a structured process to seven bidders, including two dermatology-led platforms and four PE-backed aesthetics platforms, and closed at 8.3x EBITDA to a Quad-C-backed dermatology roll-up. The recurring membership book and the practitioner diversification were the headlines that drove the auction — the buyers paid for predictability."

— John M. Salony

For a parallel view of how PE platforms underwrite related healthcare service businesses, our 2026 veterinary practice valuation analysis walks through the same provider-concentration and recurring-revenue logic in the vet space.

Find Out What Your Med Spa Is Worth

Use our free med spa valuation calculator for an instant estimate based on revenue, injector mix, EBITDA margin, and membership/recurring revenue. Then schedule a confidential consultation to walk through the buyer pool active for your specific book.

Schedule a Confidential Consultation

Frequently Asked Questions

Are PE firms still buying med spas in 2026?
Yes, and aggressively. The institutional money is still being deployed even though the 2021-2022 frenzy has moderated. PE-backed platforms fall into three groups: dedicated aesthetics chains (LaserAway, Ideal Image, Skin Laundry), dermatology-led aesthetics platforms (Advanced Dermatology & Cosmetic Surgery, Dermatology Associates [Quad-C], U.S. Dermatology Partners, Forefront Dermatology, Pinnacle Dermatology, Skin Spectrum), and independent regional roll-ups. The serious PE engagement threshold is roughly $1M of adjusted EBITDA — below that, you compete for individual and small-platform attention at 3x-5x SDE; above that, with multi-location footprint, PE platforms engage seriously and multiples clear 7x-9x for the best businesses.
What are PE buyers scrutinizing harder in med spa deals in 2026?
Three things. First, practitioner concentration — any single injector above 30% of bookings is a red flag and buyers will discount the multiple or require retention escrows. Second, regulatory compliance — state-by-state physician supervision rules vary widely, and PE buyers want documented, defensible medical-director relationships and protocols. Third, revenue diversification — med spas with 60%+ of revenue from Botox face price compression risk as new neuromodulators enter the market; the platforms pay premium multiples for med spas with strong recurring membership programs, body-contouring revenue, skin treatments, and other longer-cycle services. Practitioner retention contracts (signed before close) materially increase what PE platforms will pay.